Neri-Páez E, Huerta-Gómez JC, Hernández-Toriz N, Ramírez-Reyes AG

Language: Spanish
References: 20
Page: 33-38
PDF size: 111.89 Kb.

ABSTRACT

Introduction: Testicular cancer represents 1% of all the malignant tumors, being commonest between 15 and 34 years of age. The incidence has been increased of 3.26 to 5.44/100.000 cases, from 1973 to the date. The multimodal therapy of nonseminomatous testicular cancer in clinical stage 1 (CS1) includes monitoring, nerve preserving retroperitoneal lymphadenectomy (PRL) and chemotherapy. The PRL has demonstrated to be curative in 90% of patients, still with presence of retroperitoneal metastasis of low volume. Objectives: To know retroperitoneal metastasis frequency and complications in patients with nonseminomatous testicular cancer clinical stage 1 subjected to PRL. Material and methods: From January 1995 to December 2005, in the Urology Service of the Hospital de Oncología, of the CMN Siglo XXI clinical files of patients with diagnosis of nonseminomatous testicular cancer, in clinical stage 1, put under PRL, were reviewed, analyzing demographic variables, presence of retroperitoneal metastasis and complications of the procedure. Results: 126 files of patients with diagnosis of nonseminomatous testicular tumor clinical stage 1 subjected to PRL were reviewed, registering: average of age was 24 years (17-44 years), and folloup of 54 months (7-127 months) we found right testicular tumor in 67 patients (53.2%); 36% were teratomas, 30.2% embrionary cancer, 28.6% teratocarcinoma, 3.2% viteline sac tumor and 1.6% cariocarcinoma. The histological study of retroperitoneal limph nodes was positive in 20.63% of the cases and the overall rate of complications was 19.9%. In 66 patients it was possible to evaluate the retrograde ejaculation appeared in 3 patients (5.5%). Conclusions: Patients with nonseminomatous testicular cancer CS1 must be put under a careful protocol of evaluation to determine the more appropriate treatment which can be monitoring, chemotherapy or PRL. Considering that the opportunity of cure is essential in these patients, the PRL is a reasonable treatment alternative for germinal cells tumors in clinical stage 1.

REFERENCES

1. Brown LM, Potreen LM, Hoover RN, Devesa SS, Aselton P, Flannery JT. Testicular cancer in the United States: Trends in incidence and mortality. Int J Epidemiol 1986; 15: 164-70.

2. Boring CC, Squires TS, Tong T. CA Cancer J Clin 1993; 43: 7-6.

3. Elbe JN, Sauter G, Epstien JL, Epstein, et al. WHO histological classification of testis tumor. Tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004, p. 218.

4. Richie JP, Steele GS. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan ED, Wein A (Eds.). Campbell’s Urology, 8th edition. Philadelphia, PA: WB Saunders; 2002.

5. Kennedy BJ, Schmidt JD, Winchester DP, et al. National survey of patterns of care for testis cancer. Cancer 1987; 60: 1921-30.

6. Bosl GJ, Goldman A, Lange PH, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981; 2: 970-3.

7. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Review of the Indiana University Experience 1965-1989. Br J Urol 1993; 71: 326.

8. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000; 163: 1788-92.

9. Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005; 174: 557-60.

10. 10.Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn LH. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma – predominant testis cancer. J Clin Oncol 2000; 18(2): 358-62.

11. 11.Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumours of the testis: experience of the german testicular cancer study group. J Urol 2003; 169: 1710-14.

12. 12.Jewett MAS, Kong YSP, Goldberg SD, Sturgeon JFG, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1998; 139: 1220.

13. 13.Donohue JP, Foster RS, Rowland RG, Birhle, Jones J, Geier G. Nerve sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 1990; 144: 287.

14. 14.Langenstroer P, Rosen MA, Griebling TL, Thrasher JB. Ejaculatory function in stage T1 nonseminomatous germ cell tumours: retroperitoneal lymph node dissection versus surveillance –a decision analysis. J Urol 2002; 168: 1396- 1401.

15. 15.Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 2005; 23(12): 2781-8.

16. 16.Divrik RT, Akdogan B, Ôzen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumours – Is shift to risk adapted policy justified? J Urol 2006; 176(4): 1424.30.

17. 17.Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumours: indications and limitations. J Urol 1996; 156(3): 1108-13.

18. 18.Foster RS. Modified retroperitoneal lymphadenectomy. BJU International 2004; 94(6): 941-55.

19. 19.Rabbani F, Sheinfeld J, et al. Low volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and Prognostic factors for relapse. J Clin Oncol 2001; 19(7): 2020-5.

20. 20.Albers P, Siener R, Kliesch S, Weissbach L, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumours: results of the german testicular cancer study group trial. J Clin Oncol 2003; 21(8): 1505- 12.